{"id":"W4410158978","doi":"10.1182/blood.2025028357","title":"Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Swedish Orphan Biovitrum; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Servier; Astellas Pharma; Genentech; Y-mAbs Therapeutics; MacroGenics; Syndax Pharmaceuticals; Pfizer; Incyte; Agios Pharmaceuticals; American Society of Pediatric Hematology/Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Kite Pharma; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Discontinuation; Myeloid leukemia; Tolerability; Population; Adverse effect; Refractory (planetary science); Phases of clinical research; Oncology; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001718698,0.000696236,0.000774233,0.0001372691,0.0001502262,0.0008025354,0.0004270039,0.0004578609,0.001919531],"category_scores_gemma":[0.0004777512,0.0001855358,0.0007861441,0.0001989415,0.0004365449,0.0005071561,0.0002524119,0.001431004,0.0004786863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005984543,"about_ca_system_score_gemma":0.0007039842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004185145,"about_ca_topic_score_gemma":0.001266042,"domain_scores_codex":[0.9997227,0.0001406082,0.00002065485,0.00003648902,0.00003709809,0.00004259498],"domain_scores_gemma":[0.9996618,0.00008125006,0.0000852739,0.00004293787,0.00002517475,0.0001035465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4561639,0.04179848,0.05713265,0.001933541,0.004575426,0.001082609,0.0005478768,0.00631862,0.135384,0.001360686,0.01989344,0.2738088],"study_design_scores_gemma":[0.2343582,0.5585425,0.1238222,0.0001999755,0.003483369,0.002671706,0.0002573066,0.004444688,0.04056241,0.0005826679,0.03096728,0.0001076954],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931091,0.003388344,0.0001924001,0.000228021,0.00005069944,0.0002338999,0.0006297891,0.00004112647,0.002126599],"genre_scores_gemma":[0.9934314,0.002217859,0.0003945511,0.0003434572,0.0001077884,0.0001692325,0.001915907,0.00001283529,0.001406976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001919531,"threshold_uncertainty_score":0.00908947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0174446013702846,"score_gpt":0.300949740871285,"score_spread":0.2835051395010004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}